The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
|Videos|July 1, 2022
Dr. Brugarolas on unmet needs in the renal cell carcinoma treatment paradigm
Author(s)Urology Times staff
Understanding the mechanisms of treatment resistance is among the areas of unmet need, says James Brugarolas, MD, PhD.
Advertisement
James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, lists several areas of unmet need in the treatment paradigm for patients with renal cell carcinoma.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5